(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 9 August 2001 (09.08.2001)

(51) International Patent Classification7:

PCT

C12N

(10) International Publication Number WO 01/57190 A2

(21)	International Ap	plication Number:	PCT/US01/0	4098
(22)	International Fil	ing Date: 5 February	2001 (05.02.2	2001)
(25)	Filing Language	•	En	glish
(26)	Publication Lang	guage:	En	glish
(30)	Priority Data:			
	09/496,914	3 February 2000	(03.02.2000)	US
	09/560,875	27 April 2000	(27.04.2000)	US
	09/598,075	20 June 2000	(20.06.2000)	US
	09/620,325	19 July 2000	(19.07.2000)	US
	09/654,936	1 September 2000	(01.09.2000)	US
	09/663,561	15 September 2000	(15.09.2000)	US
	09/693,325	20 October 2000	(20.10.2000)	US
i	09/728,422	30 November 2000	(30.11.2000)	US

Boulevard, Foster City, CA 94404 (US). ZHOU, Ping [CN/US]; 7595 Newcastle Drive, Cupertino, CA 95014 (US). XU, Chongjun [US/US]; 4918 Manitoba Drive, San Jose, CA 95130 (US). CAO, Yicheng [CN/US]; 260 N. Mathilda Avenue, #E6, Sunnyvale, CA 94086 (US). MA, Yunquing [CN/US]; 280 W. California Avenue, #206, Sunnyvale, CA 94086 (US). ZHAO, Qing, A. [CN/US]; 1556 Kooser Road, San Jose, CA 95118 (US). WANG, Dunrui [CN/US]; 932 La Palma Place, Milpitas, CA 95035 (US). WANG, Jian-Rui [CN/US]; 744 Stendahl Lane, Cupertino, CA 95014 (US). ZHANG, Jie [CN/US]; 4930 Poplar Terrace, Campbell, CA 95008 (US). REN, Feiyan [US/US]; 7703 Oak Meadow Court, Cupertino, CA 95014 (US). CHEN, Rui-hong [US/US]; 1031 Flying Fish Street, Foster City, CA 94404 (US). WANG, Zhi, Wei [CN/US]; 836 Alturas Avenue, #B6, Sunnyvale, CA 94085 (US). XUE, Aidong, J. [CN/US]; 1621 S. Mary Avenue, Sunnyvale, CA 94087 (US). YANG, Yonghong [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). WEJHRMAN, Tom [US/US]; CCSR Mol Pharm 3210, 269 W. Campus Drive, Stanford, CA 94305 (US). GOODRICH, Ryle [US/US]; 4896 Sandy Lane, San Jose, CA 95124 (US).

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	09/496,914 (CIP)
Filed on	3 February 2000 (03.02.2000)
US	09/560,875 (CIP)
Filed on	27 April 2000 (27.04.2000)
US	09/598,075 (CIP)
Filed on	20 June 2000 (20.06.2000)
US	09/620,325 (CIP)
Filed on	19 July 2000 (19.07.2000)
US	09/654,936 (CIP)
Filed on	1 September 2000 (01.09.2000)
US	09/663,561 (CIP)
Filed on	15 September 2000 (15.09.2000)
US	09/693,325 (CIP)
Filed on	20 October 2000 (20.10.2000)
US	09/728,422 (CIP)
Filed on	30 November 2000 (30.11.2000)

- (74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ; BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, EU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): HYSEQ, INC. [US/US]; 670 Almanor Avenue, Sunnyvale, CA 94086 (US).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): TANG, Y., Tom [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). LIU, Chenghua [CN/US]; 1125 Ranchero Way, Apt. #14, San Jose, CA 95117 (US). DRMANAC, Radoje, T. [YU/US]; 850 Greenwich Place, Palo Alto, CA 94303 (US). ASUNDI, Vinod [US/US]; 709 Foster City

(54) Title: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES

(57) Abstract: The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1-984, 1969-2952, 3937-3942 or 3949-3954, a full length protein coding portion of SEQ ID NO:1-984, 1969-2952, 3937-3942 or 3949-3954, a mature protein coding portion of SEQ ID NO: 1-984, 1969-2952, 3937-3942 or 3949-3954, an active domain coding portion of SEQ ID NO: 1-984, 1969-2952, 3937-3942 or 3949-3954, and complementary sequences thereof.

- 2. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide hybridizes to the polynucleotide of claim 1 under stringent hybridization conditions.
- 3. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide has greater than about 90% sequence identity with the polynucleotide of claim 1.
- 4. The polynucleotide of claim 1 wherein said polynucleotide is DNA.
- 5. An isolated polynucleotide of claim 1 wherein said polynucleotide comprises the complementary sequences.
- 6. A vector comprising the polynucleotide of claim 1.
- 7. An expression vector comprising the polynucleotide of claim 1.
- 8. A host cell genetically engineered to comprise the polynucleotide of claim 1.
- 9. A host cell genetically engineered to comprise the polynucleotide of claim 1 operatively associated with a regulatory sequence that modulates expression of the polynucleotide in the host cell.
- 10. An isolated polypeptide, wherein the polypeptide is selected from the group consisting of:
 - (a) a polypeptide encoded by any one of the polynucleotides of claim 1; and
 - (b) a polypeptide encoded by a polynucleotide hybridizing under stringent conditions with any one of SEQ ID NO: 1-984, 1969-2952, 3937-3942 or 3949-3954.

11. A composition comprising the polypeptide of claim 10 and a carrier.

12. An antibody directed against the polypeptide of claim 10.

. .

- 13. A method for detecting the polynucleotide of claim 1 in a sample, comprising:
- a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and
- b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.
- 14. A method for detecting the polynucleotide of claim 1 in a sample, comprising:
- a) contacting the sample under stringent hybridization conditions with nucleic acid primers that annual to the polynucleotide of claim 1 under such conditions;
- b) amplifying a product comprising at least a portion of the polynucleotide of claim 1; and
- c) detecting said product and thereby the polynucleotide of claim 1 in the sample.
- 15. The method of claim 14, wherein the polynucleotide is an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.
- 16. A method for detecting the polypeptide of claim 10 in a sample, comprising:
- a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and
- b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 10 is detected.
- 17. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:
- a) contacting the compound with the polypeptide of claim 10 under conditions sufficient to form a polypeptide/compound complex; and
- b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

18. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:

- a) contacting the compound with the polypeptide of claim 10, in a cell, under conditions sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and
- b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.
- 19. A method of producing the polypeptide of claim 10, comprising,
- a) culturing a host cell comprising a polynucleotide sequence selected fromm the group consisting of SEQ ID NO: 1-984, 1969-2952, 3937-3942 or 3949-3954, a mature protein coding portion of SEQ ID NO: 1-984, 1969-2952, 3937-3942 or 3949-3954, an active domain coding portion of SEQ ID NO: 1-984, 1969-2952, 3937-3942 or 3949-3954, complementary sequences thereof and a polynucleotide sequence hybridizing under stringent conditions to SEQ ID NO: 1-984, 1969-2952, 3937-3942 or 3949-3954, under conditions sufficient to express the polypeptide in said cell; and
 - b) isolating the polypeptide from the cell culture or cells of step (a).
- 20. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of any one of the polypeptides SEQ ID NO: 985-1968, 2953-3936, 3943-3948 or 3955-3960, the mature protein portion thereof, or the active domain thereof.
- 21. The polypeptide of claim 20 wherein the polypeptide is provided on a polypeptide array.
- 22. A collection of polynucleotides, wherein the collection comprising the sequence information of at least one of SEQ ID NO: 1-984, 1969-2952, 3937-3942 or 3949-3954.
- 23. The collection of claim 22, wherein the collection is provided on a nucleic acid array.
- 24. The collection of claim 23, wherein the array detects full-matches to any one of the polynucleotides in the collection.
- 25. The collection of claim 23, wherein the array detects mismatches to any one of the polynucleotides in the collection.

26. The collection of claim 22, wherein the collection is provided in a computer-readable format.

- 27. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.
- 28. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising an antibody that specifically binds to a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.

.

SEQ ID NO:	ACCESSION NUMBER	SPECIES	DESCRIPTION	SMITH- WATERMAN SCORE	M IDENTITY
115	AF110399	Homo sapiens	elongation factor Ts	1666	100
116	AF210317	Homo sapiens	facilitative glucose transporter family member GLUT9	2052	99
117	Y73328	Homo sapiens	HTRM clone 082843 protein sequence.	931	100
118	X04085	Homo sapiens	catalase	2846	100
119	AF147717	Homo sapiens	ubiquitin C-terminal hydrolase UCH37	1695	100
120	X73882	Homo sapiens	microtubule associated protein	3801	99
121	AC004882	Homo sapiens	similar to CAA16821 (PID:g3255952)	3223	100
122	M93311	Homo sapiens	metallothionein-III	421	100
123	G03827	Homo sapiens	Human secreted protein, SEQ ID NO: 7908.	557	94
124	G03827	Homo sapiens	Human secreted protein, SEQ ID NO: 7908.	222	53
125	AF232009	Homo sapiens	peroxisomal trans 2-enoyl CoA reductase	1565	99
126	AB004906	Ipomoea purpurea	transposase	146	20
127	M60165	Homo sapiens	guanine nucleotide-binding regulatory protein 2	1832	99
128	Y10319	Homo sapiens	carnitine carrier	1592	100
129	U75467	Drosophila melanogaster	Atu	937	36
130	Z21507	Homo sapiens	human elongation factor-1-delta	494	87
131	Z21507	Homo sapiens	human elongation factor-1-delta	938	100
132	Y58633	Homo sapiens	Protein regulating gene expression PRGE-26.	6745	100
133	Y58633	Homo sapiens	Protein regulating gene expression PRGE-26.	4818	95
134	M13692	Homo sapiens	alpha-1 acid glycoprotein precursor	1064	99
135	U72970	Sus scrofa	calcium/calmodulin-dependent protein kinase II isoform gamma-B	2723	99
136	G03213	Homo sapiens	Human secreted protein, SEQ ID NO: 7294.	450	100
137	AC005102	Homo sapiens	small inducible cytokine subfamily A member 24	627	99
138	AF155648	Homo sapiens	putative zinc finger protein	5855	92
139	AF144638	Homo sapiens	sphingosine-1-phosphate lyase	2977	100
140 141	AF152318 B08517	Homo sapiens Homo sapiens	protocadherin gamma A1 Amino acid sequence of a beta- tubulin antigen.	4778 5841	100
142	X56667	Homo sapiens	calretinin	1410	99
143	X92763	Homo sapiens	tafazzins	1605	100
144	Y95293	Homo sapiens	Human GEF containing NEK-like kinase substrate sGNK.	4092	99
145	AF226046	Homo sapiens	GK003	1198	100
146	M22877	Homo sapiens	cytochrome c	554	98
147	AJ272212	Homo sapiens	protein serine kinase	2196	100
148	AB026491	Homo sapiens	PICK1	2114	98
149	AB018580	Homo sapiens	hluPGFS	1699	100
150	X91868	Homo sapiens	six1	1509	100
151	AF266505	Mus musculus	pseudouridine synthase 3	2135	84
152	U29170	Drosophila melanogaster	ANON-23D-	883	43
153	G04075	Homo sapiens	Human secreted protein, SEQ ID NO: 8156.	567	99
154	AY009128	Homo sapiens	ISCU2	138	100

	,	
	·	
•		

SEQ ID NO:	ACCESSION NO.	DESCRIPTION	RESULTS*
		BINDING (CREB) PROTEIN SIGNATURE	
124	PR00041	CAMP RESPONSE ELEMENT BINDING (CREB) PROTEIN SIGNATURE	PR00041D 7.95 2.906e-09 24-41
125	BL00061	Short-chain dehydrogenases/reductases family proteins.	BL00061C 7.86 3.250e-10 212- 222
126	PD01066	PROTEIN ZINC FINGER ZINC- FINGER METAL-BINDING NU.	PD01066 19.43 6.400e-25 251-290
127	PR00318	ALPHA G-PROTEIN (TRANSDUCIN) SIGNATURE	PR00318D 16.28 1.900e-34 219- 248 PR00318B 14.79 3.455e-27 168-191 PR00318C 12.09 7.000e- 23 197-215 PR00318A 7.84 1.600e-19 35-51 PR00318E 7.23 2.500e-12 265-275
128	PR00927	ADENINE NUCLEOTIDE TRANSLOCATOR 1 SIGNATURE	PR00927E 14.93 9.743e-10 67-89 PR00927B 14.66 4.575e-09 69-91
130	BL00824	Elongation factor 1 beta/beta'/delta chain proteins.	BL00824B 9.21 7.750e-22 133- 153
131	BL00824	Elongation factor 1 beta/beta'/delta chain proteins.	BL00824C 14.58 1.000e-40 166- 204 BL00824D 14.04 1.621e-38 204-239 BL00824B 9.21 7.750e- 22 133-153 BL00824E 12.49 1.000e-19 247-263
132	PR00209	ALPHA/BETA GLIADIN FAMILY SIGNATURE	PR00209B 4.88 9.222e-13 1209- 1228
133	PR00209	ALPHA/BETA GLIADIN FAMILY SIGNATURE	PR00209B 4.88 9.222e-13 1168- 1187
134	PR00708	ALPHA-1-ACID GLYCOPROTEIN SIGNATURE	PR00708D 14.67 1.000e-27 141- 168 PR00708C 11.77 1.643e-25 98-120 PR00708B 15.15 2.174e- 24 73-95 PR00708E 13.33 1.600e-21 189-207 PR00708A 14.40 2.636e-21 51-70
135	PR00109	TYROSINE KINASE CATALYTIC DOMAIN SIGNATURE	PR00109B 12.27 8.468e-13 126- 145
136	PF00023	Ank repeat proteins.	PF00023A 16.03 3.250e-10 201- 217
137	BL00471	Small cytokines (intercrine/chemokine) C-x-C subfamily signat.	BL00471 23.92 7.480e-10 42-90
140	PR00205	CADHERIN SIGNATURE	PR00205B 11.39 5.582e-10 328- 346 PR00205B 11.39 9.018e-10 543-561
141	BL00412	Neuromodulin (GAP-43) proteins.	BL00412D 16.54 7.704e-09 976- 1027
143	PR00979	TAFAZZIN SIĞNATÜRE	PR00979E 10.83 5.950e-26 192- 214 PR00979A 11.91 8.773e-25 63-83 PR00979C 12.16 6.400e-19 108-124 PR00979D 12.38 7.955e- 19 170-185 PR00979F 10.14 3.382e-15 230-244 PR00979B 15.59 5.636e-15 94-106
145	DM00686	kw REPLICATION REP 28K 17.7K.	DM00686C 14.14 7.720e-09 111- 131
146	PR00604	CLASS IA AND IB CYTOCHROME C SIGNATURE	PR00604D 15.86 1.000e-17 87- 104 PR00604B 12.73 9.591e-16 57-73 PR00604C 10.21 8.200e-12 73-84 PR00604E 10.13 1.000e-11 106-117 PR00604A 11.13 8.800e-

		• ,	
			-
		••	••
		•	
-			

SEQ ID NO:	PFAM NAME	DESCRIPTION	p-value	PFAM SCORE
112	HSP20	Hsp20/alpha crystallin family	2.6e-20	77.7
115	EF_TS	Elongation factor TS	3.8e-63	221.1
116	sugar tr	Sugar (and other) transporter	4e-63	223.1
118	catalase	Catalase	0	1158.9
119	UCH	Ubiquitin carboxyl-terminal hydrolase, famil	1e-10	24.4
122	metalthio	Metallothionein	2.8e-25	97.4
125	adh short	short chain dehydrogenase	1.6e-45	164.6
126	KRAB	KRAB box	7.9e-25	95.9
120	G-alpha	G-protein alpha subunit	1e-249	843.0
127				
131	mito_carr EF1BD	Mitochondrial carrier proteins EF-1 guanine nucleotide exchange	2e-65 4.9e-53	227.2 189.6
		domain		
132	GYF	GYF domain	4.9e-28	106.6
133	GYF	GYF domain	4.9e-28	106.6
134	lipocalin	Lipocalin / cytosolic fatty-acid binding pr	2.1e-33	119.1
135	pkinase	Eukaryotic protein kinase domain	3.3e-86	299.8
136	ank	Ank repeat	2.2e-29	111.1
137	IL8	Small cytokines	3.1e-18	65.2
139	pyridoxal deC	(intecrine/chemokine), inter Pyridoxal-dependent decarboxylase	0.00011	19.0
	_	conse		
140	cadherin	Cadherin domain	1.3e-88	307.8
142	efhand	EF hand	5.7e-33	123.0
143	Acyltransferase	Acyltransferase	2e-29	111.2
146	cytochrome_c	Cytochrome c	1.7e-33	124.7
147	pkinase	Eukaryotic protein kinase domain	2.3e-86	300.3
148	PDZ	PDZ domain (Also known as DHR or GLGF).	1.7e-09	45.0
149	aldo ket red	Aldo/keto reductase family	7.4e-189	640.8
150	homeobox	Homeobox domain	3.2e-08	38.7
151	PseudoU_synth_	tRNA pseudouridine synthase	4.7e-57	203.0
152	abhydrolase	alpha/beta hydrolase fold	1.7e-31	118.0
153	PDZ	PDZ domain (Also known as DHR or GLGF).	1.1e-09	45.6
156	PHD	PHD-finger	7.6e-15	62.8
157	fn3	Fibronectin type III domain	0.015	21.9
158	homeobox	Homeobox domain	2.7e-27	104.1
160	PWI	PWI domain	3.9e-24	93.6
162	DnaJ	DnaJ domain	2e-06	34.8
164	Cbl_N	CBL proto-oncogene N-terminal	8e-117	401.5
166	oto lel- ! -	domain	2.15.00	+100
166	metalthio	Metallothionein	3.1e-26	100.6
167 169	LRR fibrinogen_C	Leucine Rich Repeat Fibrinogen beta and gamma chains,	0.00069 5.3e-180	26.3 611.4
170	fibrinogen C	C-term Fibrinogen beta and gamma chains,	5.3e-180	611.4
171	fibrinogen_C	C-term Fibrinogen beta and gamma chains,	1e-149	510.8
	- -	C-term		
173	homeobox	Homeobox domain	1.5e-29	111.6
174	FYVE	FYVE zinc finger	7.4e-28	103.8
175	GRIP	GRIP domain	3.9e-08	40.5
182	pkinase	Eukaryotic protein kinase domain	3.4e-71	250.0
185	CAP GLY	CAP-Gly domain	5.6e-51	182.8
107		TBC domain	2.2e-50	182.8
186	TBC			טמטוו

		• • •	:
		•	
		•	
		•	
-			

114 1098 2082 3066 787CIP2 116 8004 115 1099 2083 3067 787CIP2 117 8007 116 1100 2084 3068 787CIP2 118 8008 117 1101 2085 3069 787CIP2 119 8009 118 1102 2086 3070 787CIP2 120 8013 119 1103 2087 3071 787CIP2 121 8017 120 1104 2088 3072 787CIP2 122 8018 121 1105 2089 3073 787CIP2 123 8021 122 1106 2090 3074 787CIP2 124 8022 123 1107 2091 3075 787CIP2 125 8023 124 1108 2092 3076 787CIP2 126 8023 125 1109 2093 3077 787CIP2 <	
116 1100 2084 3068 787CIP2_118 8008 117 1101 2085 3069 787CIP2_119 8009 118 1102 2086 3070 787CIP2_120 8013 119 1103 2087 3071 787CIP2_121 8017 120 1104 2088 3072 787CIP2_122 8018 121 1105 2089 3073 787CIP2_123 8021 122 1106 2090 3074 787CIP2_124 8022 123 1107 2091 3075 787CIP2_125 8023 124 1108 2092 3076 787CIP2_126 8023 125 1109 2093 3077 787CIP2_127 8024	
117 1101 2085 3069 787CIP2_119 8009 118 1102 2086 3070 787CIP2_120 8013 119 1103 2087 3071 787CIP2_121 8017 120 1104 2088 3072 787CIP2_122 8018 121 1105 2089 3073 787CIP2_123 8021 122 1106 2090 3074 787CIP2_124 8022 123 1107 2091 3075 787CIP2_125 8023 124 1108 2092 3076 787CIP2_126 8023 125 1109 2093 3077 787CIP2_127 8024	
118 1102 2086 3070 787CIP2_120 8013 119 1103 2087 3071 787CIP2_121 8017 120 1104 2088 3072 787CIP2_122 8018 121 1105 2089 3073 787CIP2_123 8021 122 1106 2090 3074 787CIP2_124 8022 123 1107 2091 3075 787CIP2_125 8023 124 1108 2092 3076 787CIP2_126 8023 125 1109 2093 3077 787CIP2_127 8024	
119 1103 2087 3071 787CIP2_121 8017 120 1104 2088 3072 787CIP2_122 8018 121 1105 2089 3073 787CIP2_123 8021 122 1106 2090 3074 787CIP2_124 8022 123 1107 2091 3075 787CIP2_125 8023 124 1108 2092 3076 787CIP2_126 8023 125 1109 2093 3077 787CIP2_127 8024	
120 1104 2088 3072 787CIP2_122 8018 121 1105 2089 3073 787CIP2_123 8021 122 1106 2090 3074 787CIP2_124 8022 123 1107 2091 3075 787CIP2_125 8023 124 1108 2092 3076 787CIP2_126 8023 125 1109 2093 3077 787CIP2_127 8024	
121 1105 2089 3073 787CIP2_123 8021 122 1106 2090 3074 787CIP2_124 8022 123 1107 2091 3075 787CIP2_125 8023 124 1108 2092 3076 787CIP2_126 8023 125 1109 2093 3077 787CIP2_127 8024	
122 1106 2090 3074 787CIP2_124 8022 123 1107 2091 3075 787CIP2_125 8023 124 1108 2092 3076 787CIP2_126 8023 125 1109 2093 3077 787CIP2_127 8024	
123 1107 2091 3075 787CIP2_125 8023 124 1108 2092 3076 787CIP2_126 8023 125 1109 2093 3077 787CIP2_127 8024	
124 1108 2092 3076 787CIP2_126 8023 125 1109 2093 3077 787CIP2_127 8024	
125 1109 2093 3077 787CIP2_127 8024	
\	•
126 1110 2094 3078 787CIP2_128 8026	
127 1111 2095 3079 787CIP2_129 8028	
128 1112 2096 3080 787CIP2_130 8036	
129 1113 2097 3081 787CIP2_131 8038	
130 1114 2098 3082 787CIP2_132 8045	
131 1115 2099 3083 787CIP2_133 8045	
132 1116 2100 3084 787CIP2_134 8048	
133 1117 2101 3085 787CIP2_135 8048	
134 1118 2102 3086 787CIP2_136 8052	
135 1119 2103 3087 787CIP2_137 8053	
136 1120 2104 3088 787CIP2_138 8055	
137 1121 2105 3089 787CIP2_139 8059	
138 1122 2106 3090 787CIP2_140 8061	
139 1123 2107 3091 787CIP2_141 8062	
140 1124 2108 3092 787CIP2_142 8063	
141 1125 2109 3093 787CIP2_143 8064	
142 1126 2110 3094 787CIP2_144 8065	
143 1127 2111 3095 787CIP2_145 8068	3
144 1128 2112 3096 787CIP2_146 8069)
145 1129 2113 3097 787CIP2_147 8070)
146 1130 2114 3098 787CIP2_148 8074	
147 1131 2115 3099 787CIP2_149 8076	5
148 1132 2116 3100 787CIP2_150 8077	
149 1133 2117 3101 787CIP2_151 8078	
150 1134 2118 3102 787CIP2_152 8079	
151 1135 2119 3103 787CIP2_153 8087	
152 1136 2120 3104 787CIP2_154 8091	
153 1137 2121 3105 787CIP2_155 8100	
154 1138 2122 3106 787CIP2_156 8105	
155 1139 2123 3107 787CIP2_157 8106	
156 1140 2124 3108 787CIP2_158 8108	
157 1141 2125 3109 787CIP2_159 8109	
158 1142 2126 3110 787CIP2_160 8110	
159 1143 2127 3111 787CIP2_161 8112	
160 1144 2128 3112 787CIP2_162 8116	
161 1145 2129 3113 787CIP2_163 8118	
162 1146 2130 3114 787CIP2_164 8124	
163 1147 2131 3115 787CIP2 165 8125	
164 1148 2132 3116 787CIP2_166 8127	
165 1149 2133 3117 787CIP2_167 8132	
166 1150 2134 3118 787CIP2_168 8135	
167 1151 2135 3119 787CIP2_169 8137	
168 1152 2136 3120 787CIP2_170 8139	
169 1153 2137 3121 787CIP2_171 8140	
170 1154 2138 3122 787CIP2_172 8140	
171 1155 2139 3123 787CIP2_173 8140	
172 1156 2140 3124 787CIP2_174 8141	
173 1157 2141 3125 787CIP2_175 8147	<u> </u>

SEQ ID NO:	Method	Predicted beginning nucleotide location corresponding to first amino acid residue of peptide sequence	Predicted end nucleotide location corresponding to last amino acid residue of peptide sequence	Amino acid sequence (A=Alanine C=Cysteine, D=Aspartic Acid, E=Glutamic Acid, F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine, L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine, R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan, Y=Tyrosine, X=Unknown, *=Stop codon, /=possible nucleotide deletion, \=possible nucleotide insertion
				PNRARNNTHSNLHTSIGNSVWGSINTGPPNQWA SDLVSSIWSNADTKNSNMGFWDDAVKEVGPRN STNKNKNNASLSKSVGVSNRQNKKVEEEEKLLK LFQGVNKAQDGFTQWCEQMLHALNTANNLDVP TFVSFLKEVESPYEVHDYIRAYLGDTSEAKEFAK QFLERRAKQKANQQRQQQLPQQQQPPQQPP QQPQQQDSVWGMNHSTLHSVFQTNQSNNQQSN FEAVQSGKKKKKQKMVRADPSLLGFSVNASSER LNMGEIETLDDY
3086	A	675	1334	LHPAATSTAWLHVPPGLSMALSWVLTVLSLLPL LEAQIPLCANLVPVPITNATLDRITGKWFYIASAF RNEEYNKSVQEIQATFFYFTPNKTEDTIFLREYQT RQDQCIYNTTYLNVQRENGTISRYVGGQEHFAH LLILRDTKTYMLAFDVNDEKNWGLSVYADKPET TKEQLGEFYEALDCLRIPKSDVVYTDWKKDKCE PLEKQHEKERKQEEGES
3087	A	1	1575	CTPVARSMATTATCTRFTDDYQLFEELGKGAFS VVRRCVKKTSTQEYAAKIINTKKLSARDHQKLE REARICRLLKHPNIVRLHDSISEEGFHYLVFDLVT GGELFEDIVAREYYSEADASHCIHQILESVNHIHQ HDIVHRDLKPENLLLASKCKGAAVKLADFGLAIE VQGEQQAWFGFAGTPGYLSPEVLRKDPYGKPVD IWACGVILYILLVGYPPFWDEDQHKLYQQIKAG AYDFPSPEWDTVTPEAKNLINQMLTINPAKRITA DQALKHPWVCQRSTVASMMHRQETVECLRKFN ARRKLKGAILTTMLVSRNFSAAKSLLNKKSDGG VKPQSNNKNSLVSPAQEPAPLQTAMEPQTTVVH NATDGIKGSTESCNTTTEDEDLKVRKQEIIKITEQ LIEAINNGDFEAYTKICDPGLTSFEPEALGNLVEG MDFHKFYFENLLSKNSKPIHTTILNPHVHVIGED AACIAYIRLTQYIDGQGRPRTSQSEETRVWHRRD GKWLNVHYHCSGAPAAPLQ
3088	A	12	1039	SSVAEFPERVQLSQPQNWNFSGAGGAWSLDFAE QLKWSAELARLGESIMDGKQGGMDGSKPAGPR DFPGIRLLSNPLMGDAVSDWSPMHEAAIHGHQL SLRNLISQGWAVNIITADHVSPLHEACLGGHLSC VKILLKHGAQVNGVTADWHTPLFNACVSGSWD CVNLLLQHGASVQPESDLASPIHEAARRGHVEC VNSLIAYGGNIDHKISHLGTPLYLACENQQRACV KKLLESGADVNQGKGQDSPLHAVARTASEELAC LLMDFGADTQAKNAEGKRPVELVPPESPLAQLF LEREGPPSLMQLCRLRIRKCFGIQQHHKITKLVLP EDLKQFLLHL
3089	A	73	432	DMAGLMTTVTSLLFLGVCAHHIIPTGSVVLPSPCC MFFVSKRIPENRVVSYQLSSRSTCLKAGVIFTTKK GQQFCGDPKQEWVQRYMKNLDAKQKKASPRA RAVAVKGPVQRYPGNQTTC
3090	A	4627	611	LMEAGGGGGALPAGVETMVLTLGESWPVLVGR RFLSLSAADGSDGSHDSWDVERVAEWPWLSGTI RAVSHTDVTKKDLKVCVEFDGESWRKRRWIEV YSLLRRAFLVEHNLVLAERKSPEISERIVQWPAIT YKPLLDKAGLGSITSVRFLGDQQRVFLSKDLLKP IQDVNSLRLSLTDNQIVSKEFQALIVKHLDESHLL KGDKNLVGSEVKIYSLDPSTQWFSATVVNGNPA SKTLQVNCEEIPALKIVDPSLIHVEVVHDNLVTC

			•
		•	
-			
•			
 •			

Pages $\,485\ \mathrm{to}\ 6221\,$ of this application contain amino acid sequence listings. They can be obtained at the address given below.

Les pages 485 to 6221 de cette demande contiennent des listages des séquences d'acides aminés. Elles peuvent être obtenues à l'adresse indiquée ci-dessous.

World Intellectual Property Organization 34, chemin des Colombettes CH-1211 Genève 20

			• -	٦, ، ، ،
•				
	-			
•				
		-		